AFFY (Affymax) Cyclically Adjusted PS Ratio: (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Affymax Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Affymax  (OTCPK:AFFY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Affymax Cyclically Adjusted PS Ratio Related Terms


Affymax Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Affymax's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affymax Cyclically Adjusted PS Ratio Chart

Affymax Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Affymax Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AFFY vs APOP, ONTX, BTHE: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Affymax's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymax Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Affymax's Cyclically Adjusted PS Ratio falls into.



Affymax Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Affymax's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2014 is calculated as:

For example, Affymax's adjusted Revenue per Share data for the three months ended in Jun. 2014 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=0.001/238.3430*238.3430
=0.001

Current CPI (Jun. 2014) = 238.3430.

Affymax Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200409 0.125 189.900 0.157
200412 0.125 190.300 0.157
200503 0.068 193.300 0.084
200506 0.068 194.500 0.083
200509 0.068 198.800 0.082
200512 0.021 196.800 0.025
200603 0.024 199.800 0.029
200606 0.104 202.900 0.122
200609 3.078 202.900 3.616
200612 0.500 201.800 0.591
200703 0.493 205.352 0.572
200706 0.650 208.352 0.744
200709 0.703 208.490 0.804
200712 1.116 210.036 1.266
200803 1.103 213.528 1.231
200806 1.259 218.815 1.371
200809 1.421 218.783 1.548
200812 1.657 210.228 1.879
200903 1.568 212.709 1.757
200906 1.425 215.693 1.575
200909 1.539 215.969 1.698
200912 1.562 215.949 1.724
201003 1.448 217.631 1.586
201006 2.197 217.965 2.402
201009 0.689 218.439 0.752
201012 0.265 219.179 0.288
201103 0.633 223.467 0.675
201106 0.400 225.722 0.422
201109 0.371 226.889 0.390
201112 0.103 225.672 0.109
201203 1.739 229.392 1.807
201206 0.076 229.478 0.079
201209 0.374 231.407 0.385
201212 0.398 229.601 0.413
201303 0.023 232.773 0.024
201306 0.014 233.504 0.014
201309 0.000 234.149 0.000
201312 0.000 233.049 0.000
201403 0.000 236.293 0.000
201406 0.001 238.343 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Affymax Business Description

Address 630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.